Merck & Co's negotiations with Seagen over a possible takeover have stalled because the two sides cannot agree on a price, according to Bloomberg, citing people familiar with the matter
AstraZeneca and Daiichi Sankyo have the confirmatory trial data they were hoping for with Enhertu as a treatment for advanced, HER2-positive breast cancer in previously-treated patients.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
